<DOC>
	<DOCNO>NCT01756612</DOCNO>
	<brief_summary>This prospective , multicenter , observational study evaluate impact comorbidity factor hemoglobin level participant chronic kidney disease dialysis initiate treatment methoxy polyethylene glycol-epoetin beta ( Mircera ) . Data collect 9 month initiation methoxy polyethylene glycol-epoetin beta treatment .</brief_summary>
	<brief_title>A Study Assess Hemoglobin Level Depending Comorbidity Index Chronic Kidney Disease ( CKD ) Participants Not Dialysis Treated With Methoxy Polyethylene Glycol-Epoetin Beta ( COMETE )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Participants chronic kidney disease dialysis Treatmentna√Øve erythropoiesisstimulating agent ( ESAs ) , receive ESAs 6 month prior inclusion study Hemoglobin level le ( &lt; ) 10 gram per deciliter ( g/dL ) inclusion Participants treat physician decide initiate treatment methoxy polyethylene glycolepoetin beta medical reason prior study start Functional renal transplant Current participation clinical trial anemia due chronic kidney disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>